Juno Therapeutics v. Kite Pharma — Federal Circuit Wipes Out $1.2 Billion Verdict, Holds CAR-T Genus Claims Lack Written Description
The Federal Circuit reversed a $1.2 billion jury verdict for Juno, holding that patent claims covering a broad functional genus of CAR-T cell receptor constructs lacked adequate written description because the specification disclosed only a few examples that could not support the full claimed scope.